Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study
Cardiovascular Therapeutics · 2024
DOI: 10.1155/2024/4227941 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cardiovascular Therapeutics, 2024. Verfasst von Sergio Cinza-Sanjurjo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Milladoiro Health Centre Santiago de Compostela Health Area, Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Cholesterol, LDL, Primary Health Care, Dyslipidemias, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Almirall.
Abstract (Originalsprache)
Background and Aim: Since 2019, LDL‐cholesterol (LDL‐C) is the risk factor with the strictest goals and the most difficult to reach, due to its role in the development of atherosclerotic plaque and, therefore, cardiovascular risk. The objective of the TERESA‐AP study is to analyze the degree of LDL‐C control in patients followed up in primary care with lipid‐lowering drug treatment (LLT).
Methods
Observational, multicenter, cross‐sectional, nationwide study was conducted, in which 50 PC physicians recruited 929 patients who were receiving LLT during at least the preceding 6 months. The variables required to estimate the patients’ cardiovascular risk and LDL control were recorded.
Results
Nearly half of sample was women (50.5%), and the mean age was 67.8 (10.4) years. High blood pressure (65.3%) and sedentary lifestyle (59.7%) were the most frequent risk factors. Recommended goals were reached in 26.0% (95% CI: 23.3%–29.0%) of patients, with a slightly higher percentage in patients with cardiovascular disease (CVD) (26.7%), diabetes mellitus (DM) (35.5%), and a lower one in patients with chronic kidney disease (CKD) (12.1%). The most frequent drug treatments were statin monotherapy (69.0%) and statin with ezetimibe combination (27.6%), with moderate‐intensity statins being the most commonly used in both groups.
Conclusions
On average, only a quarter of the patients followed up in PC and who receive drug treatment reach their therapeutic targets. This percentage is slightly higher if the patients have CVD and DM and lower if they have CKD. The most commonly used therapeutic strategy is moderate‐intensity statins, both in monotherapy and in combination with ezetimibe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Milladoiro Health Centre Santiago de Compostela Health Area, Santiago de Compostela, Spain.
- Santiago de Compostela Research Institute (IDIS), Santiago de Compostela, Spain.
- Networking Biomedical Research Center-Cardiovascular Diseases (CIBER-CV), Madrid, Spain.
- Medicine Department Santiago de Compostela University, San Francisco Street 15701, Santiago de Compostela, Spain.
- Cardiology Department, H Ramón y Cajal 28034, Madrid, Spain.
- Department of Medicine University of Alcala 28801, Madrid, Spain.
ORCID-Profile: Sergio Cinza-Sanjurjo, Vivencio Barrios, Jose Polo-García, Vicente Pallarés-Carratalá
Förderung
- Almirall
Zitieren
APA
Cinza-Sanjurjo, S., Barrios, V., Fierro-González, D., Polo-García, J., & Pallarés-Carratalá, V. (2024). Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study. Cardiovascular Therapeutics. https://doi.org/10.1155/2024/4227941
Vancouver
Cinza-Sanjurjo S, Barrios V, Fierro-González D, Polo-García J, Pallarés-Carratalá V. Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study. Cardiovascular Therapeutics. 2024. doi:10.1155/2024/4227941
BibTeX
@article{CinzaSanjurjo2024,
author = {Cinza-Sanjurjo, Sergio and Barrios, Vivencio and Fierro-González, David and Polo-García, Jose and Pallarés-Carratalá, Vicente},
title = {Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study},
journal = {Cardiovascular Therapeutics},
year = {2024},
doi = {10.1155/2024/4227941}
}
EUVIMED